Multiple treatments that can change the course of type 1 diabetes have been identified over the last several years through the efforts of TrialNet, the Immune Tolerance Network and others. Although these immune therapies can stop disease progression in those with elevated blood sugars, the effect has proven to be transient in most study subjects. The ongoing effort of Type 1 Diabetes TrialNet, its Clinical Centers and affiliates is to continue to develop better therapies to prevent and reverse type 1 diabetes in human subjects. The Barbara Davis Center and its affiliate network has been a central contributor to these efforts from the beginning of DPT-1 through TrialNet and we hope with renewal of our Clinical Center to be able to continue to push towards these aims as well as develop the next generation of physician-scientists who can build on the work accomplished so far.
Our aim i s not only to conduct excellent clinical research which can answer the main study questions being examined: most often metabolic - development of impaired glucose tolerance, overt diabetes or reduced C-peptide, but also to develop immune biomarkers which can help us better understand the pathogenesis of disease progression and identify secondary markers of responder groups that allow us to better tailor our therapies to achieve successful prevention of T1D.
There are more than 1 .5 million with Type 1 diabetes in the United States and probably as many who may develop it over their lifetime. The cost of treating this disease and its complications is a major issue for our health care system. Type 1 Diabetes TrialNet was constituted to find therapies which would prevent and reverse this autoimmune disease. Although progress has been made to temporarily halt disease progression, more work to permanently stop it remains. It is the ongoing goal of the TrialNet Network through the excellent conduct of clinical trials and incorporation of relevant mechanistic studies to find treatments that can achieve these ends.
Showing the most recent 10 out of 71 publications
